Scarica l'app Stockscreener
35.21
0.09%
-0.03
Dopo l'orario di chiusura:
35.18
-0.03
-0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.24
Aprire:
$34.13
Volume 24 ore:
1.98M
Relative Volume:
0.90
Capitalizzazione di mercato:
$5.71B
Reddito:
-
Utile/perdita netta:
$-328.94M
Rapporto P/E:
-14.38
EPS:
-2.4487
Flusso di cassa netto:
$-266.00M
1 W Prestazione:
-4.50%
1M Prestazione:
-9.46%
6M Prestazione:
+138.71%
1 anno Prestazione:
+515.56%
Intervallo 1D:
$33.82
$35.67
Intervallo di 1 settimana:
$33.82
$39.41
Portata 52W:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
35.21 | 5.71B | 0 | -328.94M | -266.00M | -2.4487 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
COGT Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Cogent Biosciences Inc To Discuss Full SUMMIT Data at ASH Transcript - GuruFocus
[Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Technical Reactions to COGT Trends in Macro Strategies - Stock Traders Daily
Cogent Biosciences, Inc.Common Stock (NQ: COGT - The Chronicle-Journal
Cogent Biosciences, Inc. (COGT) stock price, news, quote and history - Yahoo Finance UK
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT) - seekingalpha.com
Dip Buying: What are analysts price targets for Cogent Biosciences Inc2026 Top Decliners & Risk Controlled Daily Trade Plans - baoquankhu1.vn
COGT Forecast, Price Target & Analyst Ratings | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GISTHas The Bull Case Changed? - Sahm
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - Investing News Network
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2%Should You Sell? - MarketBeat
Biotech Stocks To ConsiderApril 1st - MarketBeat
Cogent Biosciences (COGT) Advances Bezuclastinib Application - GuruFocus
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors in US - MarketScreener
Cogent Biosciences Submits New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors - MarketScreener
Cogent Biosciences Announces Submission of New Drug - GlobeNewswire
Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m By Investing.com - Investing.com Canada
COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion - Stock Titan
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts - Proactive financial news
Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - AOL.com
Stifel Initiates Coverage of Cogent Biosciences (COGT) with Hold Recommendation - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers - TipRanks
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - AOL.com
Vanguard disaggregates holdings; Cogent Biosciences (COGT) shows 0% ownership - Stock Titan
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - AOL.com
Aug Analyst Calls: Is Cogent Biosciences Inc forming a double bottomPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Assessing Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Rising Institutional Interest - Sahm
A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions - Yahoo Finance
Trading the Move, Not the Narrative: (COGT) Edition - Stock Traders Daily
RTW Investments Increases Cogent Biosciences Stake to 2.7% of PortfolioNews and Statistics - IndexBox
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million - Intellectia AI
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio UpdateNews and Statistics - IndexBox
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch - The Motley Fool
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026 - Bitget
FDA accepts Cogent’s drug filing for treatment of rare blood disorder - MSN
Cogent Biosciences stock climbs after FDA accepts key drug application - MSN
HC Wainwright Analysts Lift Earnings Estimates for COGT - MarketBeat
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND) - The Globe and Mail
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):